WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 574767
Description: L-002 is an inhibitor of p300 histone acyltransferase (KAT3B). L-002 also inhibits acetylation of histones and p53 and suppresses STAT3 activation. In vivo, L-002 potently suppressed tumor growth of TNBC cell line MDA-MB-468 xenografts.
MedKoo Cat#: 574767
Chemical Formula: C15H15NO5S
Exact Mass: 321.0671
Molecular Weight: 321.35
Elemental Analysis: C, 56.07; H, 4.71; N, 4.36; O, 24.89; S, 9.98
Synonym: L-002, L 002, L002; p300/CBP Inhibitor VI; NSC 764414
IUPAC/Chemical Name: 2,6-dimethyl-2,5-cyclohexadiene-1,4-dione 4-[O-[(4-methoxyphenyl)sulfonyl]oxime]
InChi Key: VEWFTYOFWIXCIO-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H15NO5S/c1-10-8-12(9-11(2)15(10)17)16-21-22(18,19)14-6-4-13(20-3)5-7-14/h4-9H,1-3H3
SMILES Code: COC1=CC=C(S(O/N=C2C=C(C)C(C(C)=C\2)=O)(=O)=O)C=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 321.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1. Yang, H., Pinello, C.E., Luo, J., et al. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents. Molecular Cancer Therapeutics 12(5), 610-620 (2013).